News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actavis (ACT) May Not Have It In The Bag, Valeant Pharmaceuticals International (VRX), Other Suitors Eye Forest Laboratories, Inc. (FRX)



2/20/2014 7:39:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actavis Plc’s purchase of Forest Laboratories Inc. (FRX) accelerates a pharmaceutical merger wave that stands to engulf even more drugmakers. The $21 billion transaction, which includes Forest’s net cash, is fueling the busiest 12-month period for acquisitions in the industry since 2009, according to data compiled by Bloomberg. Generic-drug companies such as Actavis and Valeant Pharmaceuticals International Inc. (VRX) are boosting growth by crossing over into specialty medicines including skin-care treatments, birth control and remedies for digestive diseases.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES